Progesterone News and Research

RSS

DMPA intake may increase risk of periodontitis, gingivitis in women

Injectable progesterone contraceptives may be associated with poor periodontal health, according to research in the Journal of Periodontology. The study found that women who are currently taking depotmedroxyprogesterone acetate (DMPA) injectable contraceptive, or have taken DMPA in the past, are more likely to have indicators of poor periodontal health, including gingivitis and periodontitis, than women who have never taken the injectable contraceptive.

7 Feb 2012

Oral contraceptive pills help relieve period pain: Study

A three decade long study has proven that oral contraceptive pills may alleviate painful periods for some women. Estimates suggest more than half of women have suffered from the condition, called dysmenorrhea, at some point.

19 Jan 2012

Two new studies focus on causes of arrhythmia and SCD

Researchers in Rhode Island Hospital's Cardiovascular Research Center have published two new studies focusing on the causes of arrhythmia and sudden cardiac death (SCD) when a genetic disorder is present.

18 Jan 2012

CutisPharma introduces FIRST - Mouthwash Kits

CutisPharma, Inc. announced the introduction of FIRST - Mouthwash BLM 4oz and FIRST - Mouthwash BLM 6oz compounding kits. These products expand the FIRST Magic Mouthwash line for CutisPharma.

21 Dec 2011

DHEA hormone may help a woman's menopausal symptoms, sex life

A new study has shown that the DHEA, a hormone mostly secreted by the adrenal glands, may be able to help a woman's menopausal symptoms, as well as giving her a better sex life.

20 Dec 2011

Vaginal progesterone decreases odds of premature delivery in women

A new study co-authored by the University of Kentucky's Dr. John O'Brien found that applying vaginal progesterone to women who are at a high risk of preterm birth significantly decreased the odds of a premature delivery.

16 Dec 2011

Vaginal progesterone safe and effective in preventing preterm birth

Women with a short cervix should be treated with vaginal progesterone to prevent preterm birth, according to a landmark study by leading obstetricians around the world. Vaginal progesterone decreased the rate of preterm birth by 42%, and significantly reduced the rate of respiratory distress syndrome and the need for mechanical ventilation, as well as a composite of several complications of premature newborns.

15 Dec 2011

Vaginal progesterone reduces rate of preterm birth and neonatal complications

A team of investigators of the National Institutes of Health housed at the Detroit Medical Center (DMC) and Wayne State University (WSU) published today that performing a cervical ultrasound in all pregnant women and treating those with a short cervix with vaginal progesterone reduces the rate of preterm birth and neonatal complications.

15 Dec 2011

Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types

Synta Pharmaceuticals Corp. Ganetespib shows potent in vitro and in vivo activity against multiple types of breast cancer including HER2-positive, ER/PR positive, triple-negative, and inflammatory breast cancer according to results presented at the San Antonio Breast Cancer Symposium.

13 Dec 2011

MRI can predict breast cancer prognosis

Quantitative magnetic resonance imaging measures were associated with prognostic tumor markers, demonstrating the potential of magnetic resonance imaging for prediction of disease prognosis and stratification of patients to appropriate therapies, according to preliminary data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

9 Dec 2011

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.

9 Dec 2011

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.

8 Dec 2011

Progesterone can benefit women with catamenial seizures: Study

Seizures in women of childbearing age commonly show patterns of exacerbation that involve hormones as a factor. Investigators today reported the favorable outcome of a multicenter randomized, double-blinded, placebo-controlled phase III clinical trial of progesterone therapy in reducing these perimenstrually exacerbated (catamenial) seizures.

3 Dec 2011

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

30 Nov 2011

Genetic, lifestyle factors and HRT increase risk of breast cancer

The risk of breast cancer is increased by genetic and lifestyle factors such as the inherited BRCA2 gene, age of having first child, or use of hormone replacement therapy (HRT).

28 Nov 2011

Benefits of hormone replacement therapy in protecting women from Alzheimer's inconclusive

A rigorous evaluation of the scientific literature reveals that the jury is still out when it comes to hormone replacement therapy and a woman's risk for Alzheimer's disease. Alzforum (http://www.alzforum.org) asked prominent scientists to analyze the results of published studies examining the effects of estrogen or estrogen-plus-progesterone therapy on women.

9 Nov 2011

GAPPS research into causes of preterm births and development of solutions

Thirteen million babies are born prematurely every year, but new funding announced today will allow for pioneering research into the causes of preterm births and the development of solutions so they can be prevented.

8 Nov 2011

Columbia Laboratories third quarter total net revenues decrease to $4.9 million

Columbia Laboratories, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2011.

3 Nov 2011

Watson third quarter net income increases 31% to $138.7 million

Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the third quarter ended September 30, 2011, an increase of 23 percent when compared to $882.4 million in the third quarter 2010. On a non-GAAP basis, net income for the third quarter 2011 increased 31 percent to $138.7 million or $1.09 per diluted share, compared to $105.9 million or $0.85 per diluted share in the third quarter 2010.

1 Nov 2011

U.S. earns a 'C' on March of Dimes 2011 Premature Birth Report Card

Preterm birth rates improved in almost every state between 2006 and 2009, and in several states the change was more than 10 percent, according to the March of Dimes 2011 Premature Birth Report Card.

1 Nov 2011